Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:ANAC
Previous Symbol
CUSIP03242010
Phone+1-650-5437500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
Anacor Pharmaceuticals (NASDAQ:ANAC) Frequently Asked Questions
What is Anacor Pharmaceuticals' stock symbol?
Anacor Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANAC."
How were Anacor Pharmaceuticals' earnings last quarter?
Anacor Pharmaceuticals Inc (NASDAQ:ANAC) announced its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.01. The biopharmaceutical company earned $17.54 million during the quarter, compared to analyst estimates of $19.53 million. The firm's revenue was up 14.9% compared to the same quarter last year. During the same period last year, the company posted ($0.30) earnings per share. View Anacor Pharmaceuticals' Earnings History.
Has Anacor Pharmaceuticals been receiving favorable news coverage?
News coverage about ANAC stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Anacor Pharmaceuticals earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.
How do I buy shares of Anacor Pharmaceuticals?
Shares of ANAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anacor Pharmaceuticals' official website?
How can I contact Anacor Pharmaceuticals?
Anacor Pharmaceuticals' mailing address is 1020 E Meadow Cir, PALO ALTO, CA 94303-4230, United States. The biopharmaceutical company can be reached via phone at +1-650-5437500.
MarketBeat Community Rating for Anacor Pharmaceuticals (NASDAQ ANAC)
MarketBeat's community ratings are surveys of what our community members think about Anacor Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
